Trial · NCT07542002
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
NCT07542002, Phase 2, Recruiting, Ningbo Medical Center Lihuili Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study. Trials, record NCT07542002. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07542002
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
- NCT number
- NCT07542002
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 37 participants, estimated
- Lead sponsor
- Ningbo Medical Center Lihuili Hospital
- Conditions
- Pancreatic Cancer
- Interventions
- Irinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.
- First posted
- 2026-04-21
- Last updated
- 2026-04-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The R0 resection rate | Through study completion, an average of 2 year. | It is defined as the proportion of subjects evaluated as having undergone R0 resection after the operation. |
| Secondary | Overall survival | Through study completion，an average of 2 year | It is defined as the time from randomization (or start of treatment) until death from any cause. |
| Secondary | Event-Free Survival | Through study completion, an average of 1 year | It is defined as the period from the date of randomization of the subjects to the occurrence of tumor progression that makes surgery impossible, postoperative recurrence/metastasis, or death, whichever occurs first. |
| Secondary | Objective Response Rate | Through study completion, an average of 2 year | It is defined as the proportion of patients whose tumor volume reduction reaches a predetermined threshold (usually complete response + partial response) and maintains the minimum time requirement. |
| Secondary | Pathological Complete Response | Through study completion, an average of 2 year | It is defined as no residual active tumor cells being found in the surgically resected tumor tissue after neoadjuvant therapy. |
| Secondary | Adverse events and A serious adverse event | Through study completion, an average of 2 year | Adverse events (AE) refer to adverse medical events that occur in patients after they receive a certain drug, but they do not necessarily have a causal relationship with the treatment. AE can be any adverse and unwanted symptoms, signs, abnormal laboratory tests or diseases, etc. A serious adverse event (SAE) refers to an adverse event that occurs during the research process and meets one or more of the following criteria: Incidents resulting in death; Life-threatening (The term "life-threatening" means that the patient is at risk of death at the time of the event/reaction; it does not mean that death may occur only when the event/reaction deteriorates further); Hospitalization is required or the current hospital stay is extended; Events that result in permanent or severe disability/loss of function; Congenital abnormalities or birth defects; Other significant medical events refer to those events/reactions that, although not immediately life-threatening, cause death or hospitali |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07542002
GET https://conductscience.org/api/trials/v1/NCT07542002/registered